Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.74 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.74 |
| ▸ | EGFR | P00533 | 11/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.73 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.73 |
| ▸ | CSF1R | P07333 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4768455 | 1.00 | KDR (0.74) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL4772881 | 0.91 | EGFR (0.66) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL4764721 | 0.89 | EGFR (0.71) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL27603008 | 0.89 | EGFR (0.71) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL4770913 | 0.87 | ERBB2 (0.69) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL27603009 | 0.87 | ERBB2 (0.69) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL4763796 | 0.87 | KDR (0.69) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL4763819 | 0.86 | EGFR (0.70) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL4767333 | 0.86 | KDR (0.68) | KDRERBB2EGFRHDAC3HDAC4 | |
| SCHEMBL4769397 | 0.86 | ERBB2 (0.70) | KDRERBB2EGFRHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101560214-B | 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives | NOVARTIS AG | 2011-05-25 | — | — | CN | disclosed |
| CN-101560214-A | 4-amino-6-phenyl-pyrrolo[2, 3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2009-10-21 | — | — | CN | disclosed |
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | NOVARTIS AG (CH) | 2004-12-02 | — | — | US | disclosed |
| CN-1538847-A | 4-amino-6-phenyl-pyrrolo [2, 3-d ] pyrimidine derivatives | ��˹��ŵ�� | 2004-10-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242600-A1 | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | DPYD, TYMP, TYMS | KDR 2234/4885ERBB2 1341/4885EGFR 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.